Preclinical studies, including seminal work by JoAnn Flynn’s group in murine TB models [116], have demonstrated that recombinant IL-12 administration significantly reduces pulmonary bacterial burden (1.5 log10 CFU reduction) and enhances granuloma resolution through IFN-γ-dependent macrophage activation, and IL-12 is even expected to be used for the prevention of TB relapse [117,118,119]. This evidence concerns the gene IFNG and tuberculosis.